# A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients

> clinical trial · VERIFIED · 2026-06-26

Status: RECRUITING · Sponsor: The First Affiliated Hospital with Nanjing Medical University · Condition: CLL (Chronic Lymphocytic Leukemia)

- Company: The First Affiliated Hospital with Nanjing Medical University
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07671378

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.